Trabectedin (ET-743) in prostate cancer: Endoplasmic reticulum stress-induced apoptotic effect

Simple item page
dc.contributor.authorAtmaca H.
dc.contributor.authorOğuz F.
dc.contributor.authorIlhan S.
dc.date.accessioned2024-07-22T08:03:42Z
dc.date.available2024-07-22T08:03:42Z
dc.date.issued2022
dc.description.abstractTrabectedin is a chemotherapy agent originating from a tunicate, Ecteinascidia turbinata. In this study, DNA-independent action mechanisms of trabectedin are investigated in prostate cancer (PCa) cells. Cell viability was assessed via XTT assay. Apoptosis was evaluated via flow cytometry. Tetramethylrodamine ethyl ester (TMRE) dye was utilized to determine mitochondrial membrane potential (MMP). Cell cycle distribution was investigated via flow cytometric analysis. Reactive oxygen species (ROS) were monitored using fluorescence CM-H2DCFDA dye. Changes in CHOP, p-eIF2α, GRP78 and p-PERK which are endoplasmic reticulum (ER) stress-involved proteins were investigated via western blot. Trabectedin induced cytotoxicity and cell cycle arrest at the G2/M phase. Trabectedin decreased MMP via ROS generation in PCa cells. ER stress-related proteins CHOP, p-eIF2α, GRP78 and p-PERK were also elevated by trabectedin treatment indicating the induction of ER stress-induced apoptosis. The results of this study show that trabectedin may be an effective chemotherapeutic for PCa. © 2022 Wiley-VCH GmbH.
dc.identifier.DOI-ID10.1111/and.14599
dc.identifier.issn03034569
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/12391
dc.language.isoEnglish
dc.publisherJohn Wiley and Sons Inc
dc.rightsAll Open Access; Gold Open Access
dc.subjectApoptosis
dc.subjectCell Line, Tumor
dc.subjectEndoplasmic Reticulum Stress
dc.subjectHumans
dc.subjectMale
dc.subjectProstatic Neoplasms
dc.subjectReactive Oxygen Species
dc.subjectTrabectedin
dc.subjectendoplasmic reticulum chaperone BiP
dc.subjectfluorescent dye
dc.subjectgrowth arrest and DNA damage inducible protein 153
dc.subjectinitiation factor 2alpha
dc.subjectmatrix metalloproteinase
dc.subjectmitogen activated protein kinase
dc.subjectreactive oxygen metabolite
dc.subjecttetramethylrodamine ethyl ester
dc.subjecttrabectedin
dc.subjectunclassified drug
dc.subjectreactive oxygen metabolite
dc.subjecttrabectedin
dc.subjectapoptosis
dc.subjectapoptotic cell percentage
dc.subjectArticle
dc.subjectcancer inhibition
dc.subjectcell cycle arrest
dc.subjectcell cycle G1 phase
dc.subjectcell viability
dc.subjectdrug mechanism
dc.subjectDU145 cell line
dc.subjectendoplasmic reticulum stress
dc.subjectflow cytometry
dc.subjectG2 phase cell cycle checkpoint
dc.subjectHEK293 cell line
dc.subjecthuman
dc.subjecthuman cell
dc.subjectIC50
dc.subjectmitochondrial membrane potential
dc.subjectoxidative stress
dc.subjectPC-3 [Human prostate carcinoma] cell line
dc.subjectprostate cancer
dc.subjectprotein expression
dc.subjectWestern blotting
dc.subjectXTT assay
dc.subjectapoptosis
dc.subjectmale
dc.subjectmetabolism
dc.subjectprostate tumor
dc.subjecttumor cell line
dc.titleTrabectedin (ET-743) in prostate cancer: Endoplasmic reticulum stress-induced apoptotic effect
dc.typeArticle

Files

Collections

Scopus Koleksiyonu